Table 1.
Antimicrobial susceptibility of imipenem-non-susceptible E. coli and K. pneumoniae from the TSAR programme, 2012–18
|
E. coli (n = 17) |
K. pneumoniae (n = 163) |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antibiotic | R (%) | I (%) | S (%) | MIC50 (mg/L) | MIC90 (mg/L) | MIC range (mg/L) | R (%) | I (%) | S (%) | MIC50 (mg/L) | MIC90 (mg/L) | MIC range (mg/L) |
| Ampicillin | 100 | 0 | 0 | >16 | >16 | >16 | 100 | 0 | 0 | >16 | >16 | >16 |
| Cefazolin | 100 | 0 | 0 | >16 | >16 | >16 | 99.4 | 0 | 0.6 | >16 | >16 | 4 to >16 |
| Cefepimea | 58.8 | 0 | 41.2 | 16 | >32 | ≤0.25 to >32 | 78.5 | 0 | 21.5 | >32 | >32 | ≤0.25 to >32 |
| Cefepime/ zidebactam | 0 | 0 | 100 | 1 | 4 | ≤0.25–4 | 0.6 | 0 | 99.4 | 1 | 4 | ≤0.25 to >32 |
| Cefotaxime | 94.1 | 0 | 5.9 | >32 | >32 | ≤1 to >32 | 96.3 | 1.2 | 2.5 | >32 | >32 | ≤1 to >32 |
| Cefoxitin | 94.1 | 5.9 | 0 | >16 | >16 | 16 to >16 | 98.2 | 0 | 1.8 | >16 | >16 | ≤4 to >16 |
| Ceftazidime | 88.2 | 0 | 11.8 | >32 | >32 | ≤0.25 to >32 | 96.3 | 1.2 | 2.5 | >32 | >32 | ≤0.25 to >32 |
| Ceftazidime/ avibactam | 29.4 | 0 | 70.6 | 2 | >32 | ≤0.25 to >32 | 9.2 | 0 | 90.8 | 2 | 8 | ≤0.25 to >32 |
| Cefuroxime | 100 | 0 | 0 | >16 | >16 | >16 | 97.5 | 0 | 2.5 | >16 | >16 | 8 to >16 |
| Imipenem | 47.1 | 52.9 | 0 | 2 | >16 | 2 to >16 | 71.2 | 28.8 | 0 | 8 | >16 | 2 to >16 |
| Imipenem/ relebactam | 29.4 | 0 | 70.6 | 1 | 8 | ≤0.125 to >16 | 16 | 8 | 76.1 | 0.5 | 4 | ≤0.125–16 |
| Meropenem | 35.3 | 11.8 | 52.9 | 1 | >32 | 0.125 to >32 | 67.5 | 4.9 | 27.6 | 8 | >32 | ≤0.06 to >32 |
| Meropenem/ vaborbactam | 5.9 | 0 | 94.1 | 0.5 | 4 | ≤0.06 to >32 | 6.7 | 11.7 | 81.6 | 2 | 8 | ≤0.06 to >32 |
| Piperacillin/ tazobactam | 70.6 | 11.8 | 17.6 | >64 | >64 | ≤4 to >64 | 87.1 | 3.1 | 9.8 | >64 | >64 | ≤4 to >64 |
| Ciprofloxacin | 82.4 | 0 | 17.6 | >16 | >16 | ≤0.03 to >16 | 91.4 | 4.9 | 3.7 | >16 | >16 | ≤0.03 to >16 |
| Delafloxacin | 76.5 | 0 | 23.5 | 8 | >32 | ≤0.06 to >32 | 97.5 | 0 | 2.5 | >32 | >32 | ≤0.06 to >32 |
| Lascufloxacin | 76.5 | 0 | 23.5 | 32 | >64 | 0.06 to >64 | 96.3 | 1.8 | 1.8 | >64 | >64 | 0.125 to >64 |
| Levofloxacin | 82.4 | 0 | 17.6 | 32 | >32 | ≤0.25 to >32 | 89 | 3.7 | 7.4 | >32 | >32 | ≤0.25 to >32 |
| Eravacycline | 23.5 | 0 | 76.5 | 0.5 | 1 | 0.125–2 | 63.2 | 0 | 36.8 | 1 | 2 | 0.25 to >8 |
| Minocycline | 23.5 | 11.8 | 64.7 | 4 | 16 | 1–32 | 27.6 | 42.9 | 29.4 | 8 | 32 | 1 to >64 |
| Omadacycline | 11.8 | 17.6 | 70.6 | 4 | 16 | 1–32 | 27.6 | 44.2 | 28.2 | 8 | 16 | 2 to >32 |
| Tigecycline | 0 | 0 | 100 | 0.5 | 2 | 0.25–2 | 0.6 | 2.5 | 96.9 | 1 | 2 | 0.25–8 |
| Amikacin | 5.9 | 0 | 94.1 | ≤4 | 16 | ≤4 to >32 | 22.7 | 0.6 | 76.7 | ≤4 | >32 | ≤4 to >32 |
| Gentamicin | 41.2 | 0 | 58.8 | 2 | >8 | ≤1 to >8 | 66.9 | 1.2 | 31.9 | >8 | >8 | ≤1 to >8 |
| Aztreonam | 88.2 | 5.9 | 5.9 | >16 | >16 | ≤1 to >16 | 86.5 | 4.9 | 8.6 | >16 | >16 | ≤1 to >16 |
| Colistin | 5.9 | 0 | 94.1 | ≤0.5 | ≤0.5 | ≤0.5 to >2 | 12.9 | 0 | 87.1 | ≤0.5 | >2 | ≤0.5 to >2 |
R, resistant; I intermediate; S, susceptible.
a
SDD and susceptible breakpoints (≤8 mg/L) for cefepime were used here.